Skip to main content

Month: March 2022

Mercury Systems receives $3.6M order for electro-optical / infrared image processing systems

ANDOVER, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a leader in trusted, secure mission-critical technologies for aerospace and defense, announced it has received a $3.6 million order from a leading defense prime contractor for electro-optical / infrared (EO/IR) image processing systems for an airborne surveillance application. The order was booked in the Company’s fiscal 2022 second quarter and is expected to be shipped over the next several quarters. Why It MattersLeading-edge real-time EO/IR processing technology enables pilots to secure unprecedented, real-time situational awareness both day and night, helping them to maintain tactical advantage in the battlefield. “This long-term customer continues to turn to Mercury for purpose-built technology that meets rigorous performance...

Continue reading

Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three months and year ended December 31, 2021 and provided a business update. Fourth Quarter Financial ResultsCash and cash equivalents:  As of December 31, 2021, the Company had $53.1 million of cash and cash equivalents compared to $89.0 million of cash and cash equivalents as of December 31, 2020. The Company expects cash burn for the full year 2022 to be between $25.0 million and $30.0 million. The Company believes its cash and cash equivalents as of December 31, 2021 will be sufficient to meet its current projected operating requirements into 2023....

Continue reading

FutureFuel Releases 2021 Results: Reports Net Income of $26.3 Million or $0.60 per Diluted Share, and Adjusted EBITDA of $33.8 Million

CLAYTON, Mo., March 15, 2022 (GLOBE NEWSWIRE) — FutureFuel Corp. (NYSE: FF) (“FutureFuel”), a manufacturer of custom and performance chemicals and biofuels, today announced financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 Financial Highlights (all comparisons are with the fourth quarter of 2020)Revenues were $107.1 million, up 115% from $49.9 million Adjusted EBITDA was $25.7 million, up 141% from $10.8 million Net income increased to $22.3 million, or $0.51 per diluted share, from $5.5 million, or $0.13 per diluted share.2021 Financial Highlights (all comparisons are with the year ended December 31, 2020)Revenues were $321.4 million, up 57% from $204.5 million Adjusted EBITDA was $33.8 million, up 16.1% from $29.2 million Net income decreased to $26.3 million, or $0.60 per diluted...

Continue reading

Shift to Acquire Fair’s Dealer Listing Marketplace Technology, Team to Expand E-commerce Auto Platform; SoftBank Group to Fully Fund Acquisition

Expands the breadth and depth of Shift’s inventory and add world-class talent to platform team Represents important step in building out Shift’s vision of owning every part of the car ownership lifecycle Shift to launch dealer marketplace product in Q2SAN FRANCISCO, March 15, 2022 (GLOBE NEWSWIRE) — Shift (Nasdaq: SFT), a leading end-to-end auto ecommerce platform transforming the used car industry with a technology-driven, hassle-free customer experience, has entered a definitive agreement to acquire certain assets of Fair Technologies (“Fair”) for a combination of cash and shares of Shift’s Class A common stock. Concurrently, Shift entered into a commitment letter with SoftBank Group Corp. (“SoftBank Group”), whereby SoftBank Group has agreed to purchase senior unsecured notes due in 2025, which will be used to fund the acquisition. “Shift...

Continue reading

Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

SANTA MONICA, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and provided a corporate update. Recent highlights include: Finance UpdateQ4 revenues of $13.8 million, an increase of 39% compared to the same period in 2020Exceeded full-year 2021 royalty revenue guidance of approximately $38 million with 2021 royalty revenue of approximately $41 million, a 49% increase over full-year 2020Full-year net income of $3.0 millionWell capitalized, with approximately $53.0 million in cash, cash equivalents and marketable securities, as of December 31, 2021Pipeline UpdateOPNT003, nasal nalmefene,...

Continue reading

European Wax Center, Inc. Reports Record Fourth Quarter and Fiscal Year 2021 Results

Announces intent to launch whole business securitization and refinancing of existing senior secured credit facilities, with portion of proceeds expected to fund one-time special dividendIssues fiscal 2022 outlook, including total revenue growth in excess of long-term framework Fourth Quarter 2021System-wide sales of $201.9 million increased 51.2% from Q4 2020 and 23.2% from Q4 2019 Total revenue of $45.1 million increased 53.8% from Q4 2020 and 35.0% from Q4 2019 Same-store sales increased 13.6% from Q4 2019 and accelerated 300 basis points sequentially GAAP net income of $4.4 million improved $8.9 million from Q4 2020 and $38.2 million from Q4 2019 Adjusted EBITDA of $15.2 million increased $9.5 million from Q4 2020 and $15.1 million from Q4 2019Fiscal Year 2021System-wide sales of $796.5 million increased 69.9% from fiscal 2020...

Continue reading

Talis Biomedical Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results

Conference call and webcast today at 4:30pm Eastern/1:30pm Pacific MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2021. Talis has not started its phased launch of the Talis One™ COVID-19 Test System due to challenges with manufacturing. The company has engaged in a manufacturing review process to determine appropriate next steps and undertaken initiatives to align resources and preserve cash. “Since assuming the role of CEO in December, I have spent the past three months diving into specific areas...

Continue reading

Boxed, Inc. Announces Fourth Quarter and Fiscal Year 2021 Financial Results

Completion of Business Combination in December 2021 Delivering Liquidity to Support Growth InvestmentsSuccessful Software & Services Launch Generates $20.3 Million in Fiscal Year 2021 Net RevenueFourth Quarter YoY Gross Profit Growth of 50.4%Fourth Quarter YoY Average Order Value Increased by 11.5% to $131 NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) — Boxed, Inc. (NYSE: BOXD, BOXD WS) (“Boxed” or the “Company”), an e-commerce grocery platform that sells bulk consumables and licenses its e-commerce software to enterprise retailers, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2021. “I am proud of how the entire Boxed team executed this year. Even in light of all the focus we put into our go-public process, we are pleased to be announcing results in line with the forecast released...

Continue reading

XpresSpa Group Reports Record Full Year 2021 Results

Strongest Financial Results in Company History Marks End to Banner Year Record Quarterly Revenue of $29.4 Million, Record Net Income of $3.3 Million Liquidity Position with Unrestricted Cash Balance Increases to $105.5 Million Company to Actively Repurchase Shares under Current Authorization Webcast and Conference Call Scheduled for 4:30 PM ET Today NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) — XpresSpa Group, Inc. (Nasdaq: XSPA), a travel health and wellness company, today reported record financial results for the fourth quarter and full year ending December 31, 2021. Scott Milford, XpresSpa Group CEO, stated, “We ended 2021 on a high note with our strongest financial results in company history. Quarterly revenue was $29.4 million, while net income and adjusted EBITDA reached $3.3 million and $4.5 million, respectively1, reflecting...

Continue reading

Shift Grows Revenue 167% in Q4’2021; Strong Guidance for 2022 Reflects Continued Rapid Growth with Significant Operational Efficiencies

Achieved strong revenue and units sold levels in the fourth quarter; year-over-year growth of 167% and 80%, respectively Attained Q4’2021 Total Gross Profit per unit of $1,885, an increase of 305% year-over-year Projecting approximately 2x year-over-year Q1’2022 revenue growth, at the midpoint of management guidance range Projecting full-year 2022 revenue guidance of $1.0 billion – $1.1 billion, approximately 60-70% year-over-year growth, while demonstrating significant operating leverageSAN FRANCISCO, March 15, 2022 (GLOBE NEWSWIRE) — Shift Technologies, Inc. (Nasdaq: SFT), a leading end-to-end ecommerce platform for buying and selling used cars, today reported fourth quarter financial results for the period ended December 31, 2021. Management’s commentary on fourth quarter financial results and first quarter and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.